A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 03 Feb 2017 Planned End Date changed from 1 Feb 2017 to 18 May 2017.
- 03 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 18 May 2017.
- 01 Nov 2016 Results (n=43) published in the Journal of Thoracic Oncology